Purpose Of Review: Identification of Lynch syndrome is important from an individual patient and public health standpoint. As paradigms for Lynch syndrome diagnosis have shifted in recent years, this review will discuss rationale and limitations for current strategies as well as provide an overview of future directions in the field.

Recent Findings: In recent years, the use of clinical criteria and risk scores for identification of Lynch syndrome has been augmented by universal testing of all newly diagnosed colorectal cancers with molecular methods to screen for mismatch repair deficiency with high sensitivity and specificity. Studies of implementation and outcomes of universal testing in clinical practice have demonstrated significant heterogeneity that results in suboptimal uptake and contributes to disparities in diagnosis. Emerging technologies, such as next-generation sequencing, hold significant promise as a screening strategy for Lynch syndrome. Universal testing for Lynch syndrome is being performed with increasing frequency, although real-world outcomes have demonstrated room for improvement. Future directions in Lynch syndrome diagnosis will involve optimization of universal testing workflow and application of new genetics technologies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986345PMC
http://dx.doi.org/10.1007/s11938-019-00261-2DOI Listing

Publication Analysis

Top Keywords

lynch syndrome
28
universal testing
16
identification lynch
12
syndrome diagnosis
8
future directions
8
lynch
7
syndrome
7
effective identification
4
syndrome gastroenterology
4
gastroenterology practice
4

Similar Publications

Sebaceous carcinoma in immunosuppressed patients: a narrative review.

Arch Dermatol Res

January 2025

Department of Dermatology, Columbia University Irving Medical Center, 161 Ft Washington Ave, 12th Floor, New York, NY, 10032, USA.

Sebaceous carcinoma is a rare cutaneous malignancy of sebaceous glands, but it is up to 25-fold more common in immunosuppressed individuals. In this narrative review, we examine the current literature on the pathogenesis, incidence, risk factors, prognosis, treatment, and surveillance of sebaceous carcinoma in immunosuppression and highlight practical considerations for providers who care for these patients. Increased incidence may be related to decreased immune surveillance, susceptibility to an unknown viral trigger, microsatellite instability, immunosuppressive medications, and unmasking of occult Muir-Torre Syndrome.

View Article and Find Full Text PDF

Clinicopathological features of Lynch syndrome pedigrees with MSH2 c.351G>A gene variant.

Mol Genet Genomic Med

January 2025

Department of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang, Liaoning, China.

Background: Lynch syndrome (LS) is an autosomal-dominant disorder that increases the risk of many cancers. To identify novel or rare pathogenic variants of MMR genes associated with LS, especially in Chinese pedigrees.

Methods: One four-generation Chinese Han family from northeast China with 29 members was enrolled.

View Article and Find Full Text PDF

Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy.

Eur J Cancer

December 2024

Department of Digestive Medical Oncology, Toulouse University Hospital, Toulouse, France; Toulouse Cancer Research Centre, Toulouse, France; Department of Oncogenetics, Oncopole Claudius Regaud, Toulouse, France; Groupe Génétique et Cancer, Unicancer, France. Electronic address:

Article Synopsis
  • Sarcomas are not typically associated with Lynch Syndrome (LS), but recent literature suggests a connection, prompting a national study to investigate their characteristics in LS patients.
  • The SarcLynch study included 81 patients, finding that 83% had soft-tissue sarcomas, particularly pleomorphic variants like undifferentiated pleomorphic sarcoma and pleomorphic rhabdomyosarcoma, with 40% having sarcoma as their first cancer event.
  • Results showed a high prevalence of mismatch repair deficiency and promising responses to immune checkpoint inhibitors, suggesting the need for screening and potential immunotherapy for these sarcomas.
View Article and Find Full Text PDF

Case report: Exploring Lynch Syndrome through genomic analysis in a mestizo Ecuadorian patient and his brother.

Front Med (Lausanne)

December 2024

Centro de Investigación Genética y Genómica, Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, Ecuador.

Lynch Syndrome (LS) is a hereditary disorder characterized by genetic mutations in DNA mismatch repair genes, affecting approximately 0.35% of the population. LS primarily increases the risk of colorectal cancer (CRC), as well as various other cancer types like endometrial, breast, and gastric cancers.

View Article and Find Full Text PDF

Altered chromatin landscape and 3D interactions associated with primary constitutional MLH1 epimutations.

Clin Epigenetics

December 2024

Hereditary Cancer Group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.

Background: Lynch syndrome (LS), characterised by an increased risk for cancer, is mainly caused by germline pathogenic variants affecting a mismatch repair gene (MLH1, MSH2, MSH6, PMS2). Occasionally, LS may be caused by constitutional MLH1 epimutation (CME) characterised by soma-wide methylation of one allele of the MLH1 promoter. Most of these are "primary" epimutations, arising de novo without any apparent underlying cis-genetic cause, and are reversible between generations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!